icpeptide@gmail.comThis website has been online since June 2016.

NY-ESO-1 (157-165) C165V scrambled (MSILWQLVT) peptide – Immunology – Antigens/Epitotes/Pools/Librairies

NJ-peptide offers the scrambled MSILWQLVT peptide that can be used as a negative control of NY-ESO-1 (157-165) C165V variant epitope studies. NJ-peptide also offers NY-ESO-1 (157-165) C165V (see section NY-ESO-1 (157-165) C165V). HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA),that are cell surface receptors,presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood,cell death will be initiated via apoptosis. Peptides presented by MHC class I molecule,are usually between 7 and 11 amino acids,originating from proteins expressed by the cell. SLLMWITQV peptide differes from the New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt - P78358) native SLLMWITQC peptide,whose protein is part of a well-characterized group of cancer/testis antigens (CTAs). Normally,NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas,as well as in many other solid tumors and hematological malignancies. Class I HLA molecules of the cancerous cells cited above present peptides from NY-ESO-1 protein,including SLLMWITQC,that binds the binding cleft of the HLA-A*0201 complex. NY-ESO-1 being the most immunogenic among the CTA family members,its peptides constitute attractive targets for specific immunotherapies and the stimulation of human NY-ESO-1 specific CD8+ T cells. In order to better stimulate specific cytotoxic T-cells in PBMCs and analyze by ELISPOT peptide epitope,specificity,and cytokine production,like IFN-γ,SLLMWITQV variant peptide was used,as it is known to have a higher affinity for the binding cleft of the HLA-A*0201 complex than the native peptide. Moreover,SLLMWITQV has been used with adjuvant in protein nanoparticles in order to study cell-mediated immune responses and is also used in clinical trial to study the immunological effects of vaccines containing NY-ESO-1 (157-165) C165V. IC-PEPTIDE also offers NY-ESO-1 (157-165) native peptide,as well as Biotin-NY-ESO-1 (157-165) C165V.

Technical specification

SequenceMSILWQLVT
MW1090 ,34 g/mol (C₅₁H₈₃N₁₁O₁₃S)
Purity> 95%
Counter-ionTFA Salts (see option TFA removal)
Delivery formatFreeze dried in propylene 2mL microtubes

Price

ProductSizePrice €Price $
NJ079-1MG1 mg88 €110 $